Ultragenyx Pharmaceutical Inc. | Mid-cap | Healthcare
$31.45
-0.66%
| Ultragenyx Stock Comparison:
Ultragenyx vs VertexUltragenyx vs AlnylamUltragenyx vs MadrigalUltragenyx vs Bio-TechneUltragenyx vs Corcept TherapeuticsUltragenyx vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 139.3M
Gross Profit 110.6M 79.42%
Operating Income -142.9M -102.62%
Net Income -151.1M -108.46%
EPS (Diluted) $-1.57

Balance Sheet Metrics

Total Assets 1.3B
Total Liabilities 1.2B
Shareholders Equity 151.2M
Debt to Equity 7.67

Cash Flow Metrics

Operating Cash Flow -147.4M
Free Cash Flow -182.8M

Revenue & Profitability Trend

Ultragenyx Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 560.2M 434.2M 363.3M 351.4M 271.0M
Cost of Goods Sold i 76.7M 45.2M 28.3M 16.0M 6.1M
Gross Profit i 483.5M 389.0M 335.0M 335.4M 264.9M
Gross Margin % i 86.3% 89.6% 92.2% 95.4% 97.7%
Operating Expenses
Research & Development i 697.9M 648.4M 705.8M 497.2M 412.1M
Selling, General & Administrative i 321.6M 309.8M 278.1M 220.0M 182.9M
Other Operating Expenses i - - - - -
Total Operating Expenses i 1.0B 958.2M 983.9M 717.1M 595.0M
Operating Income i -536.0M -569.2M -648.9M -381.7M -330.1M
Operating Margin % i -95.7% -131.1% -178.6% -108.6% -121.8%
Non-Operating Items
Interest Income i 36.5M 26.7M 11.1M 1.9M 7.0M
Interest Expense i 63.0M 66.0M 43.0M 29.4M 33.3M
Other Non-Operating Income -5.1M 60.0K -20.9M -43.8M 171.0M
Pre-tax Income i -567.6M -608.5M -701.7M -453.0M -185.4M
Income Tax i 1.6M -1.8M 5.7M 1.0M 1.2M
Effective Tax Rate % i 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income i -569.2M -606.6M -707.4M -454.0M -186.6M
Net Margin % i -101.6% -139.7% -194.7% -129.2% -68.8%
Key Metrics
EBITDA i -467.9M -516.9M -621.2M -368.3M -310.2M
EPS (Basic) i $-6.29 $-8.25 $-10.12 $-6.70 $-3.07
EPS (Diluted) i $-6.29 $-8.25 $-10.12 $-6.70 $-3.07
Basic Shares Outstanding i 90538118 73543862 69914225 67795540 60845550
Diluted Shares Outstanding i 90538118 73543862 69914225 67795540 60845550

Income Statement Trend

Ultragenyx Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 173.7M 213.6M 132.9M 307.6M 713.5M
Short-term Investments i 436.3M 363.6M 614.8M 432.6M 488.0M
Accounts Receivable i 121.8M 73.4M 40.4M 28.4M 23.1M
Inventory i 45.0M 34.0M 26.8M 16.2M 13.0M
Other Current Assets 40.3M 47.6M 68.9M 71.7M -
Total Current Assets i 817.1M 732.2M 883.9M 856.6M 1.3B
Non-Current Assets
Property, Plant & Equipment i 99.4M 93.8M 50.9M 74.2M 69.5M
Goodwill i 267.1M 255.1M 248.9M 219.6M 219.9M
Intangible Assets i 178.3M 166.3M 160.1M 130.8M 131.1M
Long-term Investments - - - - -
Other Non-Current Assets 62.7M 57.7M 48.3M 20.6M 8.8M
Total Non-Current Assets i 686.3M 758.8M 661.5M 665.8M 464.3M
Total Assets i 1.5B 1.5B 1.5B 1.5B 1.8B
Liabilities
Current Liabilities
Accounts Payable i 38.8M 42.1M 43.3M 17.1M 12.9M
Short-term Debt i 10.3M 12.6M 11.8M 11.1M 9.0M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 54.1M 29.2M - - -
Total Current Liabilities i 344.2M 280.4M 261.2M 181.4M 189.6M
Non-Current Liabilities
Long-term Debt i 30.0M 30.6M 19.8M 30.9M 39.3M
Deferred Tax Liabilities i 30.1M 30.1M 31.7M 33.3M 33.3M
Other Non-Current Liabilities 17.1M 12.2M 4.8M 1.0M -
Total Non-Current Liabilities i 897.0M 935.2M 931.7M 418.5M 415.6M
Total Liabilities i 1.2B 1.2B 1.2B 599.8M 605.2M
Equity
Common Stock i 92.0K 82.0K 70.0K 69.0K 67.0K
Retained Earnings i -4.0B -3.4B -2.8B -2.1B -1.6B
Treasury Stock i 3.6M 432.0K 0 - -
Other Equity - - - - -
Total Shareholders Equity i 262.3M 275.4M 352.5M 922.6M 1.2B
Key Metrics
Total Debt i 40.3M 43.2M 31.6M 42.0M 48.2M
Working Capital i 473.0M 451.7M 622.7M 675.2M 1.1B

Balance Sheet Composition

Ultragenyx Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i -569.2M -606.6M -707.4M -454.0M -186.6M
Depreciation & Amortization i 35.5M 26.0M 18.2M 13.2M 12.3M
Stock-Based Compensation i 158.0M 135.2M 130.4M 105.0M 85.7M
Working Capital Changes i 2.2M -32.8M 56.4M -33.7M 75.1M
Operating Cash Flow i -414.4M -479.3M -406.3M -357.9M 7.7M
Investing Activities
Capital Expenditures i -7.5M -44.3M -116.1M -73.1M -43.9M
Acquisitions i 0 0 -75.0M 0 -
Investment Purchases i -408.6M -526.4M -614.7M -1.0B -850.3M
Investment Sales i 413.3M 746.2M 545.1M 890.8M 720.6M
Investing Cash Flow i -5.3M 170.5M -261.7M -195.4M -179.1M
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i - - - - -
Debt Repayment i - - - - -
Financing Cash Flow i 388.0M 379.7M 490.4M 78.5M 511.0M
Free Cash Flow i -434.2M -521.6M -526.6M -411.8M -176.1M
Net Change in Cash i -31.7M 71.0M -177.5M -474.8M 339.6M

Cash Flow Trend

Ultragenyx Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -4.91
Forward P/E -5.81
Price to Book 18.89
Price to Sales 4.69
PEG Ratio 0.21

Profitability Ratios

Profit Margin -87.34%
Operating Margin -64.80%
Return on Equity -180.44%
Return on Assets -21.59%

Financial Health

Current Ratio 2.46
Debt to Equity 557.79
Beta 0.21

Per Share Data

EPS (TTM) $-5.48
Book Value per Share $1.57
Revenue per Share $6.32

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
rare 3.0B -4.91 18.89 -180.44% -87.34% 557.79
Vertex 108.0B 29.16 6.12 22.77% 31.86% 8.89
Alnylam 60.2B -209.88 240.24 -257.83% -12.96% 1,093.31
Madrigal 9.9B -19.95 13.93 -36.30% -54.68% 17.81
Bio-Techne 9.8B 136.85 5.08 3.68% 6.02% 23.14
Corcept Therapeutics 9.5B 80.64 14.96 21.70% 18.67% 1.04

Financial data is updated regularly. All figures are in the company's reporting currency.